article Open AccessTop 1% cited

Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

British Journal of Clinical Pharmacology · 2013 · Vol. 76(3) · pp. 455–466

Wolfgang Mueck✉(Bayer (Germany))Dagmar Kubitza(Bayer (Germany))Michael Becka(Bayer (Germany))

Abstract

Results suggest that rivaroxaban may be co-administered with CYP3A4 and/or P-gp substrates/moderate inhibitors, but not with strong combined CYP3A4, P-gp and Bcrp (ABCG2) inhibitors (mainly comprising azole-antimycotics, apart from fluconazole, and HIV protease inhibitors), which are multi-pathway inhibitors of rivaroxaban clearance and elimination.

Venous Thromboembolism Diagnosis and Management Pharmacogenetics and Drug Metabolism Antiplatelet Therapy and Cardiovascular DiseasesRivaroxabanKetoconazolePharmacologyCYP3A4PharmacokineticsMedicineChemistryInternal medicineWarfarinCytochrome P450

MeSH terms

RivaroxabanCytochrome P-450 CYP2J2AdolescentAdultAnticoagulantsCytochrome P-450 Enzyme SystemDrug InteractionsEnzyme InhibitorsErythromycinHumansKetoconazoleMetabolic Clearance RateMidazolamMiddle AgedMorpholines

Citations

364

FWCI

19.60

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation